Synapse

← Journal of Market Access & Health Policy

Papers in Journal of Market Access & Health Policy

Page 4 · newest first

  1. Rapid literature review: definition and methodologyJournal of Market Access & Health Policy · 2023
  2. The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMsJournal of Market Access & Health Policy · 2023
  3. Transformative potential of artificial intelligence in global health policyJournal of Market Access & Health Policy · 2023
  4. Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatmentsJournal of Market Access & Health Policy · 2023
  5. The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaireJournal of Market Access & Health Policy · 2023
  6. Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United StatesJournal of Market Access & Health Policy · 2023
  7. Quantitative revenue estimates and qualitative assessments of innovative fundraising sources for treating rare diseases in ColombiaJournal of Market Access & Health Policy · 2023
  8. Artificial intelligence and remote patient monitoring in US healthcare market: a literature reviewJournal of Market Access & Health Policy · 2023
  9. Implementation of equity and access in Indian healthcare: current scenario and way forwardJournal of Market Access & Health Policy · 2023
  10. Projecting direct medical costs and productivity benefits of improving access to advanced therapy for rheumatoid arthritis: a projection modelling studyJournal of Market Access & Health Policy · 2023
  11. Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare settingJournal of Market Access & Health Policy · 2023
  12. Health-related quality of life in health states corresponding to different stages of perianal fistula associated with Crohn’s disease: a quantitative evaluation of patients and non-patients in JapanJournal of Market Access & Health Policy · 2023
  13. Cost-effectiveness of infant hypoallergenic formulas to manage cow’s milk protein allergy in FranceJournal of Market Access & Health Policy · 2022
  14. Innovative technologies for reverse total shoulder arthroplasty in Australia: Market access challenges and implications for patients, decision-makers, and manufacturersJournal of Market Access & Health Policy · 2022
  15. Machine-learning prediction for hospital length of stay using a French medico-administrative databaseJournal of Market Access & Health Policy · 2022
  16. Proposal of International Council for Harmonization (ICH) Guideline for the Approval of BiosimilarsJournal of Market Access & Health Policy · 2022
  17. Impact of the COVID-19 pandemic on the conduct of clinical trials: a quantitative analysisJournal of Market Access & Health Policy · 2022
  18. Systematic literature review on implicit factors influencing the HTA deliberative processes in EuropeJournal of Market Access & Health Policy · 2022
  19. Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trialsJournal of Market Access & Health Policy · 2022
  20. An integrated valuation model for payer and investorJournal of Market Access & Health Policy · 2022
  21. Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence ScenarioJournal of Market Access & Health Policy · 2022
  22. Cost-saving prediction model of transfer to palliative care for terminal cancer patients in a Japanese general hospitalJournal of Market Access & Health Policy · 2022
  23. Psychometric validation of a patient-reported single-item assessment of ‘Good Day Bad Day’ in a neurogenic orthostatic hypotension population treated with droxidopaJournal of Market Access & Health Policy · 2022
  24. Burden of illness associated with pneumococcal infections in Japan - a targeted literature reviewJournal of Market Access & Health Policy · 2021
  25. Modeling long-term health and economic implications of new treatment strategies for Parkinson’s disease: an individual patient simulation studyJournal of Market Access & Health Policy · 2021
  26. Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approachJournal of Market Access & Health Policy · 2021
  27. Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use DisorderJournal of Market Access & Health Policy · 2021
  28. Accelerating patient access to oncology medicines with multiple indications in EuropeJournal of Market Access & Health Policy · 2021
  29. A conceptual framework to develop a patient-reported experience measure of the quality of mental health care: a qualitative study of the PREMIUM project in FranceJournal of Market Access & Health Policy · 2021
  30. Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary diseaseJournal of Market Access & Health Policy · 2021
  31. Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief reviewJournal of Market Access & Health Policy · 2021
  32. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)Journal of Market Access & Health Policy · 2021
  33. Bright line or lottery? On significance and value in medical decision makingJournal of Market Access & Health Policy · 2021
  34. The effects of market concentration on health care price and quality in hospital markets in Ibadan, NigeriaJournal of Market Access & Health Policy · 2021
  35. Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemiaJournal of Market Access & Health Policy · 2021
  36. Informing decision makers seeking to improve vaccination programs: case-study SerbiaJournal of Market Access & Health Policy · 2021
  37. Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in GermanyJournal of Market Access & Health Policy · 2020
  38. An algorithm to generate correlated input-parameters to be used in probabilistic sensitivity analysesJournal of Market Access & Health Policy · 2020
  39. The impact of patent expiry on drug prices: insights from the Dutch marketJournal of Market Access & Health Policy · 2020
  40. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countriesJournal of Market Access & Health Policy · 2020
  41. Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcomeJournal of Market Access & Health Policy · 2020
  42. Health economic evaluation of gene replacement therapies: methodological issues and recommendationsJournal of Market Access & Health Policy · 2020
  43. Chinese guidelines related to novel coronavirus pneumoniaJournal of Market Access & Health Policy · 2020
  44. Transitioning to community-based mental health service delivery: opportunities for UkraineJournal of Market Access & Health Policy · 2020
  45. Health-related quality of life of patients after ischaemic stroke treated in a provincial hospital in PolandJournal of Market Access & Health Policy · 2020
  46. Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UKJournal of Market Access & Health Policy · 2020
  47. Gene therapy randomised clinical trials in Europe – a review paper of methodology and designJournal of Market Access & Health Policy · 2020
  48. Understanding the global measurement of willingness to pay in healthJournal of Market Access & Health Policy · 2020
  49. Organizational aspect in healthcare decision-making: a literature reviewJournal of Market Access & Health Policy · 2020
  50. Clinical efficacy assessment in severe vernal keratoconjunctivitis: preliminary validation of a new penalties-adjusted corneal fluorescein staining scoreJournal of Market Access & Health Policy · 2020